Scholars Central

Conference abstract

The challenges and possible solutions for transferring cell therapy from the bench to the industry, quality, cost and manufacturing efficiency

Authors: Ohad Karnieli

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In the last decade, it has been proven that cell therapy works in the lab, in preclinical settings and in small scale clinical trials. The need for large quantities of cells with high quality becomes crucial as product candidates advance into clinical trials. Technologies are evolving to allow production of large quantities of cells under GMP conditions including cell factories, hollow fibers and bioreactors. Nevertheless, high quantities of cells open new questions and challenges of cell quality, identity, reproducibility and cost. Bioreactor technology brings to the cell therapy industry the opportunity to manufacture large quantities of cells in a tightly controlled and monitored manner, lowering relatively the cost of goods manufactured resulting in a product and process for cell therapy commercialization. This advantage however holds within it many unmet challenges due to its pioneering nature. These challenges include the fact that most of the data and understanding of cells culturing that was generated over the years was collected on 2 dimensional, semi-controlled growth conditions, whereas, bioreactors are 3 dimensional and fully controlled, these changes in conditions have been proven to effect the cell characterization and phenotype. Once the growth conditions have been established the bioreactor advantages kicks in opening new challenges of downstream processing leading to automation to insure cell quality. The talk will describe some of the main challenges accounted during the development of the GMP manufacturing technology for PLX (PLacental eXpanded) cell product candidates and some of the bottlenecks opening methods developed in Pluristem?s pilot and manufacturing facilities.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Ohad Karnieli”